Leukemia Clinical Trials

Find Leukemia Clinical Trials Near You

RAT-HEMATO : Return to Work After Malignant Hemopathy

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their pre-cancer life can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of return-to-work self-efficacy is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: f
View:

• Patient with hematological malignancy controlled after treatment

• Induction/consolidation chemotherapy completed (excluding maintenance therapy)

• Patient aged 18 to 55

• Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy

• Patient who has not yet returned to work since diagnosis of hematological malignancy

• Signed informed consent form

Locations
Other Locations
France
Angers University hospital
RECRUITING
Angers
Brest University Hospital, Morvan Site
RECRUITING
Brest
Caen University hospital
NOT_YET_RECRUITING
Caen
Service Hématologie, Cholet Hospital
NOT_YET_RECRUITING
Cholet
Le Havre Hospital Group
NOT_YET_RECRUITING
Montivilliers
Pays de Morlaix Hospital
NOT_YET_RECRUITING
Morlaix
Rennes University Hospital, Pontchaillou site
NOT_YET_RECRUITING
Rennes
Centre Henri Becquerel
RECRUITING
Rouen
Rouen University Hospital
NOT_YET_RECRUITING
Rouen
Tours University Hospital, Bretonneau Site
RECRUITING
Tours
Contact Information
Primary
Jérome PAILLASSA, MD
Jerome.Paillassa@chu-angers.fr
02 41 35 44 72
Backup
Aline SCHMIDT, MD
AlSchmidt@chu-angers.fr
02 41 35 44 82
Time Frame
Start Date: 2024-09-27
Estimated Completion Date: 2028-03
Participants
Target number of participants: 264
Treatments
Experimental: Experimental arm with return-to-work after cancer consultation
No_intervention: Standard arm without with return-to-work after cancer consultation
Patient are treated according to usual care, according to local practice.
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Angers

This content was sourced from clinicaltrials.gov